← Oncology Approval Tracker

FDA DECISION ·

Pluvicto + ARPI

lutetium Lu 177 vipivotide tetraxetan with an androgen receptor pathway inhibitor · Novartis

FDA approvalNew or expanded indicationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with PSMA-positive metastatic prostate cancer that is androgen pathway modulation-naïve or -sensitive, in combination with an androgen receptor pathway inhibitor.

LAMPGEN ANALYSIS

Why it matters

Radioligand therapy moves into an earlier metastatic treatment setting. PSMAddition compared adding Pluvicto with an androgen pathway inhibitor alone.

What research teams should watch

PSMA imaging, isotope supply, nuclear medicine staffing and radiation-safety workflows affect when patients can start. Coverage should separate an approved option from local delivery capacity.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

PSMA-selected radioligand studies

PRIMARY RECORDS

Sources